144 related articles for article (PubMed ID: 20503316)
1. Treatment with valproic acid ameliorates ADHD symptoms in fragile X syndrome boys.
Torrioli M; Vernacotola S; Setini C; Bevilacqua F; Martinelli D; Snape M; Hutchison JA; Di Raimo FR; Tabolacci E; Neri G
Am J Med Genet A; 2010 Jun; 152A(6):1420-7. PubMed ID: 20503316
[TBL] [Abstract][Full Text] [Related]
2. Modest reactivation of the mutant FMR1 gene by valproic acid is accompanied by histone modifications but not DNA demethylation.
Tabolacci E; De Pascalis I; Accadia M; Terracciano A; Moscato U; Chiurazzi P; Neri G
Pharmacogenet Genomics; 2008 Aug; 18(8):738-41. PubMed ID: 18622267
[TBL] [Abstract][Full Text] [Related]
3. A double-blind, parallel, multicenter comparison of L-acetylcarnitine with placebo on the attention deficit hyperactivity disorder in fragile X syndrome boys.
Torrioli MG; Vernacotola S; Peruzzi L; Tabolacci E; Mila M; Militerni R; Musumeci S; Ramos FJ; Frontera M; Sorge G; Marzullo E; Romeo G; Vallee L; Veneselli E; Cocchi E; Garbarino E; Moscato U; Chiurazzi P; D'Iddio S; Calvani M; Neri G
Am J Med Genet A; 2008 Apr; 146A(7):803-12. PubMed ID: 18286595
[TBL] [Abstract][Full Text] [Related]
4. Autism spectrum disorders and attention-deficit/hyperactivity disorder in boys with the fragile X premutation.
Farzin F; Perry H; Hessl D; Loesch D; Cohen J; Bacalman S; Gane L; Tassone F; Hagerman P; Hagerman R
J Dev Behav Pediatr; 2006 Apr; 27(2 Suppl):S137-44. PubMed ID: 16685180
[TBL] [Abstract][Full Text] [Related]
5. Cognitive and behavioral profile of fragile X boys: correlations to molecular data.
Backes M; Genç B; Schreck J; Doerfler W; Lehmkuhl G; von Gontard A
Am J Med Genet; 2000 Nov; 95(2):150-6. PubMed ID: 11078566
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic characterization of the FMR1 gene and aberrant neurodevelopment in human induced pluripotent stem cell models of fragile X syndrome.
Sheridan SD; Theriault KM; Reis SA; Zhou F; Madison JM; Daheron L; Loring JF; Haggarty SJ
PLoS One; 2011; 6(10):e26203. PubMed ID: 22022567
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylases suppress CGG repeat-induced neurodegeneration via transcriptional silencing in models of fragile X tremor ataxia syndrome.
Todd PK; Oh SY; Krans A; Pandey UB; Di Prospero NA; Min KT; Taylor JP; Paulson HL
PLoS Genet; 2010 Dec; 6(12):e1001240. PubMed ID: 21170301
[TBL] [Abstract][Full Text] [Related]
8. Opposing Effects of Valproic Acid Treatment Mediated by Histone Deacetylase Inhibitor Activity in Four Transgenic
Vent-Schmidt RYJ; Wen RH; Zong Z; Chiu CN; Tam BM; May CG; Moritz OL
J Neurosci; 2017 Jan; 37(4):1039-1054. PubMed ID: 28490005
[TBL] [Abstract][Full Text] [Related]
9. ADHD symptoms in children with FXS.
Sullivan K; Hatton D; Hammer J; Sideris J; Hooper S; Ornstein P; Bailey D
Am J Med Genet A; 2006 Nov; 140(21):2275-88. PubMed ID: 17022076
[TBL] [Abstract][Full Text] [Related]
10. Unstable mutations in the FMR1 gene and the phenotypes.
Loesch D; Hagerman R
Adv Exp Med Biol; 2012; 769():78-114. PubMed ID: 23560306
[TBL] [Abstract][Full Text] [Related]
11. Small Molecules Targeting H3K9 Methylation Prevent Silencing of Reactivated
Kumari D; Sciascia N; Usdin K
Genes (Basel); 2020 Mar; 11(4):. PubMed ID: 32230785
[TBL] [Abstract][Full Text] [Related]
12. Reciprocal changes in DNA methylation and hydroxymethylation and a broad repressive epigenetic switch characterize FMR1 transcriptional silencing in fragile X syndrome.
Brasa S; Mueller A; Jacquemont S; Hahne F; Rozenberg I; Peters T; He Y; McCormack C; Gasparini F; Chibout SD; Grenet O; Moggs J; Gomez-Mancilla B; Terranova R
Clin Epigenetics; 2016; 8():15. PubMed ID: 26855684
[TBL] [Abstract][Full Text] [Related]
13. [Can the behavioural phenotype of fragile X syndrome be attributed to mental retardation and to attention deficit hyperactivity disorder?].
Artigas-Pallarés J; Brun-Gasca C
Rev Neurol; 2004 Jan 1-15; 38(1):7-11. PubMed ID: 14730483
[TBL] [Abstract][Full Text] [Related]
14. Valproic acid and ADHD symptoms in fragile X syndrome: more evidence is needed.
Sahu JK
Am J Med Genet A; 2010 Oct; 152A(10):2681; author reply 2682. PubMed ID: 20734428
[No Abstract] [Full Text] [Related]
15. The Influence of Hyperactivity, Impulsivity, and Attention Problems on Social Functioning in Adolescents and Young Adults With Fragile X Syndrome.
Chromik LC; Quintin EM; Lepage JF; Hustyi KM; Lightbody AA; Reiss AL
J Atten Disord; 2019 Jan; 23(2):181-188. PubMed ID: 25731183
[TBL] [Abstract][Full Text] [Related]
16. Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium.
Scheffer RE; Kowatch RA; Carmody T; Rush AJ
Am J Psychiatry; 2005 Jan; 162(1):58-64. PubMed ID: 15625202
[TBL] [Abstract][Full Text] [Related]
17. Partial FMRP expression is sufficient to normalize neuronal hyperactivity in Fragile X neurons.
Graef JD; Wu H; Ng C; Sun C; Villegas V; Qadir D; Jesseman K; Warren ST; Jaenisch R; Cacace A; Wallace O
Eur J Neurosci; 2020 May; 51(10):2143-2157. PubMed ID: 31880363
[TBL] [Abstract][Full Text] [Related]
18. STEP inhibition reverses behavioral, electrophysiologic, and synaptic abnormalities in Fmr1 KO mice.
Chatterjee M; Kurup PK; Lundbye CJ; Hugger Toft AK; Kwon J; Benedict J; Kamceva M; Banke TG; Lombroso PJ
Neuropharmacology; 2018 Jan; 128():43-53. PubMed ID: 28943283
[TBL] [Abstract][Full Text] [Related]
19. New perspectives of valproic acid in clinical practice.
Činčárová L; Zdráhal Z; Fajkus J
Expert Opin Investig Drugs; 2013 Dec; 22(12):1535-47. PubMed ID: 24160174
[TBL] [Abstract][Full Text] [Related]
20. Favorable response of ADHD with giant SEP to extended-release valproate.
Miyazaki M; Ito H; Saijo T; Mori K; Kagami S; Kuroda Y
Brain Dev; 2006 Aug; 28(7):470-2. PubMed ID: 16554135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
